Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

Por Liu, Yingmiao, Starr, Mark D, Brady, John C, Dellinger, Andrew, Pang, Herbert, Adams, Bonne, Theuer, Charles P, Lee, Nam Y, Hurwitz, Herbert I, Nixon, Andrew B
Publicado em 2014

A Phase 1 First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Por Rosen, Lee S., Hurwitz, Herbert I., Wong, Michael K., Goldman, Jonathan, Mendelson, David S., Figg, William D., Spencer, Shawn, Adams, Bonne J., Alvarez, Delia, Seon, Ben K., Theuer, Charles P., Leigh, Bryan R., Gordon, Michael S.
Publicado em 2012

An Open Label Phase 1b Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Por Gordon, Michael S., Robert, Francisco, Matei, Daniela, Mendelson, David S., Goldman, Jonathan W., Chiorean, E. Gabriela, Strother, Robert M., Seon, Ben K., Figg, William D., Peer, Cody J., Alvarez, Delia, Adams, Bonne J., Theuer, Charles P., Rosen, Lee S.
Publicado no Clin Cancer Res (2014)